Nanoviricides (NNVC) Enterprise Value (2010 - 2026)
Nanoviricides (NNVC) posted Enterprise Value of -$3.2 million for Q1 2026, up 37.61% sequentially from -$5.2 million in Q4 2025, and down 28.53% YoY from -$4.5 million in Q1 2025.
Nanoviricides (NNVC) Enterprise Value (2010 - 2026) Analysis & Trends
Nanoviricides has reported Enterprise Value for 17 years, with the latest figure at -$3.2 million in Q1 2026.
- Quarterly Enterprise Value fell 28.53% year-over-year to -$3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.2 million (down 28.53% YoY) and the FY2025 annual result came in at -$1.6 million, up 67.51% from the prior year.
- Enterprise Value improved to -$3.2 million in Q1 2026 per NNVC's latest filing, from -$5.2 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1.1 million in Q3 2025 and troughed at -$15.6 million in Q1 2022.
- A 5-year average of -$6.7 million and a median of -$5.2 million in 2025 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 71.79% in 2025, down 30.13% in 2025.
- Over 5 years, Enterprise Value stood at -$11.4 million in 2022, then jumped by 54.39% to -$5.2 million in 2023, then climbed by 23.88% to -$4.0 million in 2024, then tumbled by 30.13% to -$5.2 million in 2025, then soared by 37.61% to -$3.2 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$3.2 million, -$5.2 million, and -$1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 2.12 Bn |
| 10 | Nanoviricides | 29.17 Mn | 25.96 Mn | - | -3.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.21 Mn |
| Dec 31, 2025 | -5.15 Mn |
| Sep 30, 2025 | -1.10 Mn |
| Jun 30, 2025 | -1.56 Mn |
| Mar 31, 2025 | -2.50 Mn |
| Dec 31, 2024 | -3.96 Mn |
| Sep 30, 2024 | -3.90 Mn |
| Jun 30, 2024 | -4.80 Mn |
| Mar 31, 2024 | -3.30 Mn |
| Dec 31, 2023 | -5.20 Mn |
| Sep 30, 2023 | -7.00 Mn |
| Jun 30, 2023 | -8.15 Mn |
| Mar 31, 2023 | -9.70 Mn |
| Dec 31, 2022 | -11.40 Mn |
| Sep 30, 2022 | -12.90 Mn |
| Jun 30, 2022 | -14.07 Mn |
| Mar 31, 2022 | -15.60 Mn |
| Dec 31, 2021 | -17.30 Mn |
| Sep 30, 2021 | -19.70 Mn |
| Jun 30, 2021 | -20.52 Mn |